ÌìÃÀ´«Ã½

Newswise — Risk Management expert is available to explain the implications of pharma tariffs, following Donald Trump’s that his administration soon would announce “major” tariffs on pharmaceuticals.

In a summary of his recent essay, Tariff Risks and Opportunities for Pharma Manufacturers, Rossi writes:  Aiming to stabilize US drug supplies, tariffs may have the opposite effect while posing a number of key risks to pharma companies large and small. Mitigating these supply chain, operational, business and financial risks will require measured yet nimble responses and out-of-the box thinking. Leveraging advanced manufacturing technologies such as continuous manufacturing (CM) could help pharma companies mitigate risks while seizing a competitive advantage.

Rossi is the Academic Director of the Smith Enterprise Risk Consortium at the University of Maryland (UMD) and a Professor of the Practice and Executive-in-Residence at the University of Maryland’s Robert H. Smith School of Business. Before joining academia, he spent 25-plus years in the financial sector, as both a C-level risk executive at several top financial institutions and as a federal banking regulator.

Contact him via [email protected]